1. Lambotte O, Gelu-Simeon M, Maigne G, Kotb R, Buffet C, Delfraissy JF, et al. Pegylated
interferon alpha-2a-associated life-threatening Evans’ syndrome in a patient with chronic …

Background: Pts with LBCL primary refractory to or relapsed ≤ 12 mo after first-line (1L)
therapy may have poor outcomes with SOC, including salvage CT and ASCT, which …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable disease
and is most common in older people. Rituximab-CHOP (cyclophosphamide, doxorubicin, …

Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce. …

Vaccination guidelines for patients treated for hematological diseases are typically conservative.
Given their high risk for severe COVID-19, it is important to identify those patients that …

Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated with
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although the addition of …

Aim of the study Patients with cancer might have an increased risk for severe outcome of
coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome …

Background Patients with haematological malignancies have impaired antibody responses
to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 …

Introduction The aim of this study was to determine the efficacy of early tocilizumab treatment
for hospitalized patients with COVID-19 disease. Methods Open-label randomized phase II …

Simple Summary CAR T-cell therapy has emerged as the new standard of care for patients
with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), but real-world outcomes differ …